Do you want to find out what is driving the industry to engage in biosimilars and biobetters?
Would this help you assess whether your company should develop your focus in this direction?
- Success in biologic drugs
- Key patent expirations
- New technologies to improve repositioning success
- Increasing drug development costs
- Increased licensing opportunities
Do these match with your company's priorities or would you like to put another driver into the mix?
To find out what is driving companies like Teva Pharmaceuticals, Fujifilm Kyowa Kirin Biologics, RYTUS Pharmaceuticals, Merck Bioventures and Amgen to continue their involvement in this industry you need to get involved with the World Biosimilars Congress 2012!
For more updates on pharma, biotech and R&D, follow us on Twitter: @biopharmaevents or join our LinkedIn group: BioPharma- Networking for Pharmaceuticals, Biotech and R&D